TP53 and B-cell chronic lymphocytic leukemia: An R/R CLL patient with TP53 mutation and unmutated IGHV and who had no remaining standard of care was screened for inclusion in the clinical trial IMPRESS-Norway (NCT04817956) (Fig. 5a).